Kyoko Oura

1.9k total citations · 1 hit paper
72 papers, 1.2k citations indexed

About

Kyoko Oura is a scholar working on Hepatology, Epidemiology and Molecular Biology. According to data from OpenAlex, Kyoko Oura has authored 72 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hepatology, 29 papers in Epidemiology and 18 papers in Molecular Biology. Recurrent topics in Kyoko Oura's work include Liver Disease Diagnosis and Treatment (25 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and MicroRNA in disease regulation (13 papers). Kyoko Oura is often cited by papers focused on Liver Disease Diagnosis and Treatment (25 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and MicroRNA in disease regulation (13 papers). Kyoko Oura collaborates with scholars based in Japan, China and United States. Kyoko Oura's co-authors include Tsutomu Masaki, Asahiro Morishita, Joji Tani, Koji Fujita, Tomoko Tadokoro, Takako Nomura, Takashi Himoto, Hirohito Yoneyama, Hisakazu Iwama and Hideki Kobara and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Kyoko Oura

59 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review

2021 295 citations Kyoko Oura, Asahiro Morishita et al. International Journal of Molecular Sciences profile →

Peers

Countries citing papers authored by Kyoko Oura

Since Specialization

Citations

This map shows the geographic impact of Kyoko Oura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyoko Oura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyoko Oura more than expected).

Fields of papers citing papers by Kyoko Oura

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyoko Oura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyoko Oura. The network helps show where Kyoko Oura may publish in the future.

Co-authorship network of co-authors of Kyoko Oura

This figure shows the co-authorship network connecting the top 25 collaborators of Kyoko Oura. A scholar is included among the top collaborators of Kyoko Oura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyoko Oura. Kyoko Oura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genetic Polymorphisms of ALDH2 and ADH1B in Alcohol-Induced Liver Injury: Molecular Mechanisms of Inflammation and Disease Progression in East Asian Populations 2025 ·International Journal of Molecular Sciences ·Tomoko Tadokoro, Kyoko Oura, M. Nakahara, Koji Fujita, Joji Tani, Asahiro Morishita, Hideki Kobara	1
2	Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets 2025 ·Journal of Clinical Medicine ·Shima Mimura, Asahiro Morishita, Kyoko Oura, (unknown), M. Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, (unknown), Takashi Himoto, Hideki Kobara	0
3	Galectins and Liver Diseases 2025 ·International Journal of Molecular Sciences ·Shima Mimura, Asahiro Morishita, Kyoko Oura, Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara	2
4	Do Patients With Alcoholic Cirrhosis Accurately Recognize Their Alcohol Tolerance? A Study Comparing Self‐Perception and ALDH2/ADH1B Genotype 2025 ·Hepatology Research ·Tomoko Tadokoro, (unknown), Hung Tai, (unknown), Kei Takuma, Kyoko Oura, Koji Fujita, Shima Mimura, Joji Tani, Asahiro Morishita, Nobuyuki Miyatake, (unknown), Kenji Kinoshita, Hideki Kobara	0
5	A Noninvasive Method of Diagnosing Metabolic Dysfunction-Associated Steatohepatitis Using Cytokeratin-18 Fragment and FIB-3 Index 2025 ·Diagnostics ·Tomoko Tadokoro, Miwa Kawanaka, Kazuhiro Takahashi, Shinichi Aishima, (unknown), (unknown), Kei Takuma, M. Nakahara, Kyoko Oura, Koji Fujita, Kiyoyuki Kobayashi, Shima Mimura, Joji Tani, Asahiro Morishita, Reiji Haba, Tsutomu Masaki, Hideki Kobara, Masafumi Ono	0
6	Chronic Liver Disease Associated Cholangiocarcinoma: Genomic Insights and Precision Therapeutic Strategies 2025 ·Cancers ·Kyoko Oura, Asahiro Morishita, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Joji Tani, Tsutomu Masaki, Hideki Kobara	0
7	Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration 2025 ·Clinical and Translational Science ·Koji Fujita, Kei Takuma, Kyoko Oura, Tomoko Tadokoro, Asahiro Morishita, Takashi Himoto, Hideki Kobara	0
8	Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals 2024 ·Microorganisms ·Joji Tani, (unknown), Kyoko Oura, Tomoko Tadokoro, Asahiro Morishita, Hideki Kobara	3
9	Immune Microenvironment and the Effect of Vascular Endothelial Growth Factor Inhibition in Hepatocellular Carcinoma 2024 ·International Journal of Molecular Sciences ·Kyoko Oura, Asahiro Morishita, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara	8
10	Efficiency of Skeletal Muscle Mass/Weight Measurement for Distinguishing Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Analysis Using InBody Bioimpedance Devices 2024 ·Nutrients ·(unknown), (unknown), (unknown), (unknown), Akemi Gálvez, Ichiro Ishikawa, Yu Nakamura, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Asahiro Morishita, Takashi Himoto, S Miyazaki, (unknown), Yoshihiro Mori, (unknown), Hideki Kobara	2
11	Galectin-9 in Gastroenterological Cancer 2023 ·International Journal of Molecular Sciences ·Asahiro Morishita, Kyoko Oura, Tomoko Tadokoro, Tingting Shi, Koji Fujita, Joji Tani, Masanori Atsukawa, Tsutomu Masaki	12
12	Efficacy and outcome of molecular targeted therapies in elderly patients with hepatocellular carcinoma: Relative dose intensity associated with overall survival 2023 ·Cancer Medicine ·Kyoko Oura, Asahiro Morishita, Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Masafumi Ono, Takashi Himoto, Tsutomu Masaki	2
13	Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease 2023 ·Diagnostics ·(unknown), Chikara Ogawa, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, (unknown), Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki	10
14	MicroRNAs and Nonalcoholic Steatohepatitis: A Review 2023 ·International Journal of Molecular Sciences ·Asahiro Morishita, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Hideki Kobara, Masafumi Ono, Takashi Himoto, Tsutomu Masaki	9
15	Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy 2023 ·Cancers ·Kyoko Oura, Asahiro Morishita, (unknown), Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, (unknown), Chikara Ogawa, Akio Moriya, (unknown), Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Takashi Himoto, Tsutomu Masaki	7
16	Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy 2023 ·Cancers ·Kyoko Oura, Asahiro Morishita, Joji Tani, Takako Nomura, (unknown), Kei Takuma, M. Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, (unknown), Yoshihiro Nishiyama, Tsutomu Masaki	4
17	Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines 2022 ·International Journal of Molecular Sciences ·Kei Takuma, Shintaro Fujihara, Koji Fujita, Hisakazu Iwama, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Joji Tani, Tingting Shi, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Tsutomu Masaki	3
18	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study 2021 ·Cancers ·Joji Tani, Tomonori Senoh, Akio Moriya, Chikara Ogawa, Akihiro Deguchi, Teppei Sakamoto, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Koji Fujita, Hirohito Yoneyama, Hideki Kobara, Asahiro Morishita, Takashi Himoto, Akemi Tsutsui, Takuya Nagano, Koichi Takaguchi, Tsutomu Masaki	5
19	Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg 2021 ·Internal and Emergency Medicine ·Shima Mimura, Koji Fujita, Kei Takuma, M. Nakahara, Kyoko Oura, Tomoko Tadokoro, Hideki Kobara, Joji Tani, Asahiro Morishita, Takashi Himoto, Tsutomu Masaki	8
20	Role of microRNA-210-3p in hepatitis B virus-related hepatocellular carcinoma 2020 ·American Journal of Physiology-Gastrointestinal and Liver Physiology ·Asahiro Morishita, Koji Fujita, Hisakazu Iwama, Taiga Chiyo, Shintaro Fujihara, Kyoko Oura, Tomoko Tadokoro, Shima Mimura, Takako Nomura, Joji Tani, Hirohito Yoneyama, Kiyoyuki Kobayashi, Hideki Kamada, Yu Guan, Akira Nishiyama, Keiichi Okano, Yasuyuki Suzuki, Takashi Himoto, Kunitada Shimotohno, Tsutomu Masaki	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact